>
Switch to:

Biogen Owner Earnings per Share (TTM)

: 0.08 (As of Sep. 2021)
View and export this data going back to 1991. Start your Free Trial

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Biogen's Owner Earnings per Share (TTM) ended in Sep. 2021 was $0.08. It's Price-to-Owner-Earnings ratio for today is 3374.25.


The historical rank and industry rank for Biogen's Owner Earnings per Share (TTM) or its related term are showing as below:

NAS:BIIB' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.28   Med: 20.35   Max: 4222.78
Current: 3416.96

7.28
4222.78

During the past 13 years, the highest Price-to-Owner-Earnings ratio of Biogen was 4222.78. The lowest was 7.28. And the median was 20.35.


NAS:BIIB's Price-to-Owner-Earnings is ranked lower than
89% of the 44 Companies
in the Drug Manufacturers industry.

( Industry Median: 17.71 vs. NAS:BIIB: 3416.96 )

Biogen's Earnings per Share (Diluted) for the three months ended in Sep. 2021 was $2.22. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2021 was $10.22. It's PE Ratio ratio for today is 26.41.

Biogen's EPS without NRI for the three months ended in Sep. 2021 was $2.22. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2021 was $10.22. It's PE Ratio without NRI ratio for today is 26.41.


Biogen Owner Earnings per Share (TTM) Historical Data

The historical data trend for Biogen's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Owner Earnings per Share (TTM)
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.35 12.34 23.84 32.09 22.93

Biogen Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Owner Earnings per Share (TTM) Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.06 22.93 16.60 5.21 0.08

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Owner Earnings per Share (TTM), along with its competitors' market caps and Owner Earnings per Share (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen Owner Earnings per Share (TTM) Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Owner Earnings per Share (TTM) distribution charts can be found below:

* The bar in red indicates where Biogen's Owner Earnings per Share (TTM) falls into.



Biogen Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Biogen's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income 1,546
Depreciation, Depletion and Amortization 463
Change In Deferred Tax -813
5Y Average of Maintenance Capital Expenditure 827
Change In Working Capital -357
Shares Outstanding (Diluted Average) 149

1. Start with "Net Income" from income statement. Biogen's Net Income for the trailing twelve months (TTM) ended in Sep. 2021 was $1,546 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Biogen's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Sep. 2021 was $463 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Biogen's Change In Deferred Tax for the trailing twelve months (TTM) ended in Sep. 2021 was $-813 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $827 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Biogen's 5-Year Average Maintenance Capital Expenditure = $827 Mil

5. "Change In Working Capital" is from cashflow statement. Biogen's Change In Working Capital for the trailing twelve months (TTM) ended in Sep. 2021 was $-357 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Biogen's Shares Outstanding (Diluted Average) for the months ended in Sep. 2021 was 148.600 Mil.

Biogen's Onwer Earnings Per Share for Sep. 2021 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 1545.8 +462.7+-813
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-826.92445706222+-356.8)/148.600
=0.08

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=269.94/0.08
=3374.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Biogen Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Biogen's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen Business Description

Biogen logo
Industry
Healthcare » Drug Manufacturers NAICS : 325412 SIC : 2834
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Executives
Mcdonnell Michael R officer: EVP, Chief Financial Officer C/O IQVIA HOLDINGS INC. 83 WOOSTER HEIGHTS ROAD DANBURY CT 06810
Gregory Ginger officer: EVP, Human Resources C/O BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142
Kramer Robin officer: VP, Chief Accounting Officer 999 VANDERBILT BEACH ROAD 3RD FLOOR NAPLES FL 34109
Sherwin Stephen A director C/O CELL GENESYS, INC. 500 FORBES BLVD. SOUTH SAN FRANCISCO CA 94080
Hawkins William A director MEDTRONIC INC 710 MEDTRONIC PKWY, MS LC310 MINNEAPOLIS MN 55432-5604
Dorsa Caroline director BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142
Papadopoulos Stelios director 3 SOMERSET DRIVE SOUTH GREAT NECK NY 11020
Pangia Robert W director 3965 FREEDOM CIRCLE SANTA CLARA CA 95054
Leaming Nancy director C/O HOLOGIC INC BEDFORD MA 01730
Rowinsky Eric K director IMCLONE SYSTEMS INCORPORATED 180 VARICK STREET, 6TH FLOOR NEW YORK NY 10014
Denner Alexander J director C/O SARISSA CAPITAL MANAGEMENT LP 660 STEAMBOAT ROAD, 3RD FLOOR GREENWICH CT 06830
Posner Brian S director 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142
Mulligan Richard director C/O ICAHN CAPITAL LP 767 FIFTH AVENUE, SUITE 4700 NEW YORK NY 10153
Mantas Jesus B director BIOGEN INC. 225 BINNEY STREET CAMBRIDGE MA 02142
Galdes Alphonse officer: EVP Pharmaceutical Oper & Tech BIOGEN INC. 225 BINNEY ST. CAMBRIDGE MA 02142

Biogen Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)